We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kezar Life Sciences Inc (KZR) USD0.001

Sell:$13.42 Buy:$13.44 Change: $0.29 (2.11%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Change: $0.29 (2.11%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
Change: $0.29 (2.11%)
Market closed |  Prices as at close on 6 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company is developing small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase II clinical trials in lupus nephritis, dermatomyositis, and polymyositis. In addition, KZR-261 is an anti-cancer clinical candidate targeting the Sec61 translocon and the protein secretion pathway. The Company is focusing its initial development of KZR-616 in severe, chronic and orphan immune-mediated diseases. The Company’s principal operations are in South San Francisco, California.

Contact details

4000 Shoreline Ct Ste 300
United States
+1 (650) 8225600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$674.78 million
Shares in issue:
49.15 million
United States
US dollar

Key personnel

  • Christopher Kirk
    President, Chief Scientific Officer, Director
  • John Fowler
    Chief Executive Officer, Director
  • Marc Belsky
    Chief Financial Officer, Secretary
  • Vassiliki Economides
    Senior Vice President - Strategy and External Affairs
  • Noreen Henig
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.